User login
Key clinical point: During long-term follow-up, exocrine pancreatic insufficiency (EPI) was observed in more than half of the patients who underwent curative gastrectomy and had completed oncological treatment for gastric adenocarcinoma. Postoperative radiotherapy as an adjunct to adjuvant chemotherapy was a serious risk factor for EPI development.
Major finding: Fecal elastase-1 (FE-1) less than 200 μg/g, considered a measure of EPI, was present in 63.8% of patients. A higher proportion of patients with low FE-1 (less than 100 μg/g) received adjuvant chemoradiotherapy vs. those with moderate FE-1 (100-200 μg/g; P = .012) and normal FE-1 (less than 200 μg/g; P less than .001).
Study details: This study included 69 patients with gastric cancer who underwent total or subtotal curative gastrectomy with D2 lymphadenectomy and had long-term disease-free survival success. Patients were followed up for 16-120 months.
Disclosures: No specific funding source was identified. The authors declared no conflicts of interest.
Source: Surmelioglu A et al. Pancreatology. 2021 Apr 1. doi: 10.1016/j.pan.2021.03.019.
Key clinical point: During long-term follow-up, exocrine pancreatic insufficiency (EPI) was observed in more than half of the patients who underwent curative gastrectomy and had completed oncological treatment for gastric adenocarcinoma. Postoperative radiotherapy as an adjunct to adjuvant chemotherapy was a serious risk factor for EPI development.
Major finding: Fecal elastase-1 (FE-1) less than 200 μg/g, considered a measure of EPI, was present in 63.8% of patients. A higher proportion of patients with low FE-1 (less than 100 μg/g) received adjuvant chemoradiotherapy vs. those with moderate FE-1 (100-200 μg/g; P = .012) and normal FE-1 (less than 200 μg/g; P less than .001).
Study details: This study included 69 patients with gastric cancer who underwent total or subtotal curative gastrectomy with D2 lymphadenectomy and had long-term disease-free survival success. Patients were followed up for 16-120 months.
Disclosures: No specific funding source was identified. The authors declared no conflicts of interest.
Source: Surmelioglu A et al. Pancreatology. 2021 Apr 1. doi: 10.1016/j.pan.2021.03.019.
Key clinical point: During long-term follow-up, exocrine pancreatic insufficiency (EPI) was observed in more than half of the patients who underwent curative gastrectomy and had completed oncological treatment for gastric adenocarcinoma. Postoperative radiotherapy as an adjunct to adjuvant chemotherapy was a serious risk factor for EPI development.
Major finding: Fecal elastase-1 (FE-1) less than 200 μg/g, considered a measure of EPI, was present in 63.8% of patients. A higher proportion of patients with low FE-1 (less than 100 μg/g) received adjuvant chemoradiotherapy vs. those with moderate FE-1 (100-200 μg/g; P = .012) and normal FE-1 (less than 200 μg/g; P less than .001).
Study details: This study included 69 patients with gastric cancer who underwent total or subtotal curative gastrectomy with D2 lymphadenectomy and had long-term disease-free survival success. Patients were followed up for 16-120 months.
Disclosures: No specific funding source was identified. The authors declared no conflicts of interest.
Source: Surmelioglu A et al. Pancreatology. 2021 Apr 1. doi: 10.1016/j.pan.2021.03.019.